Status:
TERMINATED
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.
Detailed Description
Current research involving \[18F\]-florbetapir in relationship to cardiac amyloid has taken advantage of the ability of the radiopharmaceutical to bind specifically to amyloid fibrils. It has previous...
Eligibility Criteria
Inclusion
- Patients aged \> 18 years are eligible.
- Patient must provide informed consent to participate in the study protocol.
- All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).
- Planned plasma cell-directed chemotherapy.
- A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.
- Patients must be able to undergo PET-CT imaging
- Patients must be able to complete 6-minute walk test
Exclusion
- Severe claustrophobia
- Pregnancy
- Allergy to F-18 florbetapir
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03333551
Start Date
October 1 2020
End Date
May 8 2023
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226